Injectable Drug Delivery is an industry focused on two overarching topics the development of the device & the interaction between drug product and device. The 2024
Injectable Drug Delivery conference brings together a complete big pharma speaker line-up providing technical updates on the relationship between drug product formulation and the device primary packaging, with considerations for formulation strategies, extractables & leachables and toxicological testing of injectable devices.
This conference brings case studies from senior big pharma representatives providing an opportunity to discuss formulation considerations in depth for parenteral packaging, this is the perfect opportunity to benchmark your drug delivery programme and optimise the development of your injectable portfolio.
What will you gain?
- Evaluate how devices can be co-developed alongside drug products to foster a collaborative approach to improve biocompatibility and effective toxicological testing
- Expand on design strategies for injectable delivery of advanced modalities, including cell and gene therapies, large molecule delivery and sub-zero device requirements
- Learn through focused presentations tailored to a technical device development and primary packaging audience, exploring vial material and primary component selection, silicone layer thickness studies and standardisation of primary container formats
- Benefit from spotlight sessions focusing on sustainable device materials featuring industry leaders, Novo Nordisk and Johnson & Johnson, offering comprehensive perspectives on material development and selection through to disposal
- Learn how major device developers are streamlining product development and CMC practices for effective compliance throughout and post-NDA/MAA approval
Who should attend
Executives, Directors, VPs, Heads, Principals, Managers, Scientists, Researchers of:
- Autoinjectors
- Wearables
- Device Engineering
- Human Factors
- CMC
- Injectables
- Sterile Manufacturing
- Packaging
- Regulatory Affairs
Featured Speakers
- Berna Kosekaya, Regulatory Professional, Novo Nordisk
- Cedric Gysel, Manager, Sustainable Innovation & Circular Economy Solutions at the Office of Sustainability, Johnson & Johnson
- Christian Proff, Senior Verification Engineer, Roche
- Cinzia Rotella, Project Leader, Sanofi
- Clemens Gunther, Director, Senior Expert Nonclinical Safety, Bayer AG
- Estefania Dos Anjos, Senior Product Specialist, TÜV SÜD
- Fatima Bennai-Sanfourche, Senior Director of QA & RA Compliance for Medical Devices and eHealth, Bayer AG
- George Moore-Arthur, Senior Global Regulatory Professional, Novo Nordisk
- Hiroki Hasegawa, Assistant Research Manager, Mitsubishi Gas Chemical Company, Inc
- Julian Dixon, Senior Director, AstraZeneca
- Marc Egen, Head of Primary Packaging & Process Development, Boehringer Ingelheim Pharma Gmbh & Co. KG
- Morgan Amsler, Director of Business Development, ApiJect Systems, Corp.
- Ryan Noble, Associate Director, Devices, GSK
- Selenge Erdenechimeg, Global Regulatory Specialist | RA Device Combination Products, Novo Nordisk
- Simon Wilson, Device Development Lead, Pfizer
- Soumen Das, Associate Scientific Fellow, Takeda
- Victoria Ludlow, Global Change Facilitator, BioPhorum
Please fill in your name and email to receive the Conference Agenda of this event.
Venue
Hilton London Kensington
179-199 Holland Park Ave, Kensington, W11 4UL
London, UK
